Enanta Pharmaceuticals (ENTA) News
NASDAQ: ENTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.62-0.36 (-4.51%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ENTA news summary
We found 5 recent headlines mentioning Enanta Pharmaceuticals (ENTA): 3 in the past week and 5 in the past 30 days, most often from Nasdaq, Business Wire. For price context, ENTA is down 4.51% at $7.62. The most recent story, "Enanta Pharmaceuticals Becomes Oversold (ENTA)", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Enanta Pharmaceuticals headlines
- Enanta Pharmaceuticals Becomes Oversold (ENTA)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a…Nasdaq
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026Enanta Pharmaceuticals, Inc. reported its financial results for the fiscal fourth quarter and year ended September 30, 2026. Total revenue was $12.9 million for the three months ended September 30,…Nasdaq
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological…Business Wire
- Unified Patent Court Rules Enanta Pharmaceuticals, Inc. Patent EP 4 051 265 InvalidEnanta Pharmaceuticals, Inc. announced that on October 29, 2026, the Unified Patent Court of the European Union released its decision concluding that European Patent No. EP 4 051 265 is invalid. The…Nasdaq
- Enanta Pharmaceuticals, Inc. Announces Planned Retirement of CEO Jay R. Luly, Ph.D. by February 1, 2027On October 28, 2026, Enanta Pharmaceuticals, Inc. announced that Jay R. Luly, Ph.D., age 70, intends to retire as President and Chief Executive Officer by February 1, 2027, following 23 years of…Nasdaq